To identify whether patients with diabetes have a higher incidence of sensorineural hearing loss than the general population and examine whether control of diabetes is related to severity of hearing loss. Study Design: Retrospective database review; complete data mining of electronic medical record from 1989 to present. Setting: Tertiary referral center. Patients: Electronic medical records from 53,461 nondiabetic age-matched patients and 12,575 diabetic patients were reviewed. Main Outcome Measures: Presence or absence of diabetes and/or sensorineural hearing loss, serum creatinine, pure tone hearing (dB), speech discrimination (%), serum cholesterol, and triglycerides.
The relationship between diabetes mellitus and hearing loss has been debated for many years. Jordao (1) in 1857 published a case report of a diabetic patient with hearing loss. Edgar (2) in 1915 was the first to report a high-frequency sensorineural hearing loss (SNHL) in a diabetic patient. Some authors conclude that there is no relationship between hyperglycemia and hearing loss; however, the bulk of the literature supports a poorly defined association.
The link between diabetes and SNHL makes intuitive sense, given the documented neuropathic and microvascular complications of diabetes and the complex blood supply of the inner ear. Most audiometric studies of hearing in patients with diabetes show a mild to moderate high-frequency SNHL (3), although Celik et al. (4) noted higher thresholds in diabetic patients at all frequencies tested. Cullen and Cinnamond (3) showed no difference in speech discrimination scores among diabetic patients and a normal population. The effects of different variables such as duration of diabetes, blood sugar control, and presence of end-organ damage on hearing loss have not yet been clarified, despite several studies of this topic. Part of the difficulty in identifying the effects of diabetes on hearing is the presence of comorbidities, such as hypertension and atherosclerosis, which could potentially affect hearing. Furthermore, the largest studies in this area have examined several hundred patients, which limit the conclusions that these studies can draw because of insufficient statistical power.
Although many reports in the literature have evaluated the relationship between these two diseases, to our knowledge no large-scale study of the laboratory and audiometric data in diabetic patients with SNHL has been published. This study is a retrospective analysis of laboratory and audiometric data of diabetic patients with SNHL, using a large computer database at the Veterans Affairs (VA) Maryland Health Care System, which is composed of three hospitals and several free-standing clinic sites. By combining sophisticated search engines with archival electronic records, we were able to study large populations and examine the effect of diabetes on hearing.
PATIENTS AND METHODS
After Institutional Review Board approval through the University of Maryland School of Medicine was obtained, the Maryland VA database, which is a completely electronic medical record system dating back to 1989, was searched for patients carrying the diagnosis of SNHL based on International Classification of Diseases (ICD) code data. The VA Maryland Health Care system has a large population of patients who are receiving care for only a single problem. To create a subset of more comparable comorbidities, patients who had diagnoses of only psychiatric illnesses, substance abuse, or human immunodeficiency virus infection were eliminated from this study. There remained 66,036 patients who had other ICD diagnoses in outpatient encounters, beyond the isolated reasons for encounters noted above. From that group of 66,036 patients, 8,062 had SNHL. In an earlier database analysis, patients with diabetes were identified from outpatient encounters (from all VA system clinics), inpatient diagnosis coding, or prescriptions for diabetic medications or testing materials, which was available by accessing a central computer. Overall 12,575 of the 66,036 study patients had diabetes, but that diagnosis encompassed a very wide spectrum, from diet-controlled diabetes to diabetes requiring the use of insulin. Serum creatinine, total cholesterol, low-density lipoprotein (LDL) cholesterol, triglycerides, and hemoglobin A1C levels in patients with diabetes (according to standard laboratory technique) were calculated for each group as the average of the numeric data over the previous 5 years. Laboratory data were classified into different ranges specific for each laboratory test.
Audiometric data was gathered from the group with SNHL and diabetes (1,888 patients). One thousand six hundred and forty-four complete audiograms were accessible to us. Pure tone average was calculated from four frequencies (500 Hz, 1,000 Hz, 2,000 Hz, 4,000 Hz). Speech discrimination scores, calculated using standard spondaic and monosyllabic word lists, were also gathered for each of these patients. The averages of each were calculated. Statistical analysis was done by 2 , and analysis of variance by use of the SPSS software package.
RESULTS
The prevalence of diabetes in the group of patients with SNHL was 23%, compared with 19% in the group without hearing loss. The prevalence of SNHL in the diabetic group was 13.1%, compared with 10.3% in the group without diabetes, which was statistically significant (p < 0.05). Laboratory data relating to cardiovascular disease was examined for four different groups: patients without diabetes or SNHL (Group 1), nonpatients with diabetes with SNHL (Group 2), patients with diabetes without SNHL (Group 3), and patients with diabetes with SNHL (Group 4). The average creatinine levels for each group, respectively, were 1.29, 1.28, 3.84, and 3.41 mg/dL. The average total cholesterol levels, respectively, were 195. 16, 198.90, 195 (Table 1) . There was no statistically significant difference based on the presence or absence of SNHL; however, the diabetic group had a significantly higher average creatinine level (3.78 mg/dL) than did the nondiabetic group (1.29 mg/dL).
Audiometric data from patients with diabetes and SNHL were compiled. The average pure tone average in the right ear was 52.25 dB (median, 52 dB); in the left ear it was 53 dB (median, 52 dB). The average speech discrimination score in the right ear was 81.26% (median, 88%); in the left ear it was 80.59% (median, 88%). Individual pure tone averages and speech discrimination scores were correlated to individual creatinine, cholesterol, LDL, and triglyceride levels as well as age, using analysis of variance. Creatinine levels were the only laboratory value to show a correlation with the audiometric data. Patients were divided into five groups based on creatinine. (Group 1: creatinine <1; Group 2: creatinine Յ1.5; Group 3: 1.5 < creatinine Յ 2; Group 4: 2 < creatinine Յ 2.5; Group 5: creatinine > 2.5). For those patients with a creatinine level less than 1.0 mg/dL, the average pure tone average and speech discrimination scores were 51.7 dB and 82.0%, respectively. For those patients with a creatinine level greater than 2.5 mg/dL (Group 5), those values were 58 dB and 72.5%, which was significant (p < 0.05) (Fig. 1) . There was no significant difference in patient age between the individual groups.
DISCUSSION AND LITERATURE REVIEW
It is evident from a review of the otolaryngology literature that the relationship between diabetes and SNHL is complex. Most authors have concluded that patients with diabetes have worse hearing; however, a few authors, for example Harner (5) and Shuknecht (6), have denied a relationship between the two. Axelsson et al. (7) stated, "When the hearing in patients with diabetes is analyzed with respect to age group means, the results are essentially normal." However, they did admit that some patients had a few abnormal findings, such as highfrequency pure tone loss, impaired speech discrimination ability, and abnormally decreased stapedial reflex thresh- (8) included patients with insulin-dependent diabetes mellitus as well as patients with non-insulin-dependent diabetes mellitus (NIDDM). Speech discrimination scores were generally seen not to be significantly different in diabetic patients, as shown by Cullen and Cinnamond (3). However, Huang et al. (8) observed a 7% worse discrimination score in diabetic patients. Snashall (9) observed lowered stapedial reflex thresholds in a small subgroup of seven patients, indicating recruitment and cochlear loss. This same group observed tone decay only at high frequencies.
According to Cullen and Cinnamond, male patients with diabetes had worse hearing than female patients with diabetes. They surmised that this may have been due to occupational noise exposure. However, Taylor and Irwin (10) observed that female patients with diabetes had significantly greater hearing loss than male patients with diabetes. Most studies in the literature reported no differences between the sexes. Age is another variable that could play a role in hearing loss. Axelsson et al. (7) showed that the incidence of pure tone hearing loss increased with age in patients with diabetes, even after correction for presbycusis. Both processes involve progressive high-frequency losses. Potentially, the effects of diabetes could act synergistically with the processes underlying presbycusis to increase hearing loss.
The duration of diabetes in relationship to hearing loss has also been investigated, with no clear conclusion. Celik et al. (4) observed that as the duration of diabetes increased to 15 years, the incidence of hearing loss increased. After 15 years of diabetes, the influence on hearing loss was not significant. However, Axelsson et al. (7) observed that age-matched patients with diabetes treated with insulin had better hearing that those patients treated with oral medications. In addition, the duration of diabetes of those patients treated with insulin was ten years longer than those treated orally. Wackym and Linthicum (11, 12) observed that diabetic patients treated with diet alone had more severe hearing loss than those taking oral hypoglycemic agents, who had worse hearing than the patients taking insulin. This concept lends itself to the belief that aggressive therapy of diabetes leads to less hearing loss.
Attributing hearing loss to diabetes alone is often difficult because of other vascular diseases in these patients and because of compounding variables such as presbycusis. Duck et al. (13) studied the interaction of hypertension in patients with IDDM and hearing loss. They observed that hypertension and diabetes had a synergistic effect on high-frequency SNHL. The microvascular effects of hypertension are similar to those of diabetes, making these data plausible. This concept is important because the prevalence of hypertension in patients with diabetes varies between 10% and 80%, according to different reports. Intuitively, diabetic patients with retinopathy should have more hearing loss, given the similarity of the microvascular blood supply of the ear to that of the eye. Jorgensen (14) supports this, reporting hearing loss to be twice as common in diabetic patients with proliferative retinopathy.
The pathogenic effects of diabetes on the ear can be broadly grouped into neuropathic, angiopathic, and a combination of the two. The tissue effects of diabetes are thought to be related to the polyol pathway, where glucose is reduced to sorbitol. Sorbitol accumulation is implicated in neuropathy by causing a decrease in myoinositol content, abnormal phosphoinositide metabolism, and a decrease in Na+/K+ ATPase activity (15) . Mak- ishima and Tanaka (16) observed severe atrophy of the spiral ganglion in the basal and middle turns of the cochlea in diabetic patients with SNHL. They also observed that the VIIIth nerve showed signs of myelin degeneration, with fibrosis of the perineurium. This group also observed that atherosclerosis, a well-documented consequence of diabetes and hypertension, was responsible for neuronal degeneration in the inner ear. Jorgensen (14) was the first to study the histopathologic properties of temporal bones in patients with diabetes with hearing loss, and observed thickening of the walls of the vasa nervorum of the VIIIth nerve, leading to acoustic neuropathy. Jorgensen also noted microangiopathic changes in the stria vasculariz. Wackym and Linthicum (11) observed microangiopathic changes in the endolymphatic sac, stria vasculariz, and basilar membrane. The diabetic patients with microangiopathic changes in the endolymphatic sac were noted to have the greatest degree of hearing loss.
Genetic factors may also play a role in SNHL in a small subset of the population with diabetes and hearing loss. Van den Ouweland et al. (17) observed a mutation in mitochondrial tRNA in a small subset of patients with maternally inherited diabetes with SNHL. Kadowaki et al. (18) observed a similar mutation in mitochondrial DNA in the same type of patients. Since then, a variety of mitochondrial disorders that cause hearing loss have been identified; however, these seem to be uncommon. Recently, a small study demonstrated abnormalities of outer hair cell function and abnormal auditory brainstem responses in patients with diabetes (19) .
Using a rat model of diabetes, investigators have studied the histologic effect of hyperglycemia on the inner ear. Smith et al. (20) observed that the basement membranes of IDDM-induced rats (by streptozotocin injection, which causes pancreatic destruction) were nearly twice as thick as those of control rats. McQueen et al. (21) performed a similar experiment in a strain of rats with NIDDM (SHR/N-cp) and observed that NIDDM alone did not cause statistically significant basement membrane thickening. Nageris et al. (22) studied an inbred diabetic rat model (Sabra) and saw no statistical difference in the inner or outer hair cells counts or in stria vasculariz morphology.
Because many of the previous studies give conflicting evidence and their samples were small, we used a data mining approach to examine a large pool of patients. The VA started maintaining electronic medical records in 1989. This allows the examination and correlation of large pools of data over long periods of time. It is well documented that diabetes is a major cause of chronic renal failure by causing glomerular basement membrane thickening as well as hyalinization of afferent and efferent arterioles, leading to glomerulosclerosis and proteinaceous depositions in the kidney (15) . Diabetes also causes accelerated atherosclerosis by glycosylation of various lipoproteins (15) . Despite this, creatinine, total cholesterol, LDL cholesterol, and triglyceride levels were not statistically different between the diabetic populations with or without SNHL. Although the average creatinine level was higher in patients with diabetes than in those without diabetes (3.78 mg/dL vs. 1.29 mg/dL), total cholesterol and LDL levels were slightly lower in the diabetic population than in the nondiabetic population (195.44 mg/dL and 117.93 mg/dL, compared with 195.55 mg/dL and 122.13 mg/dL). However, the triglyceride levels were higher in the diabetic group (192.57 mg/dL vs. 156.99 mg/dL). This perhaps is because patients with diabetes are more aggressively treated with antilipemic medications that lower LDL and total cholesterol but have a lesser effect on triglyceride levels.
We observed that the prevalence of SNHL was higher in the diabetic population than in the nondiabetic population (13.1% and 10.3%, respectively, p < 0.05). This study also showed that in patients with diabetes and SNHL, worsening creatinine levels-and therefore worsening microvascular disease-led to worse hearing. For example, those with an average creatinine level below 1 mg/dL had an average pure tone average of 51.7 dB and an average speech discrimination score of 82%, compared with those with a creatinine level above 2.5 mg/dL had values of 58 dB and 72.5%, respectively (p < 0.05). Hearing loss also progressed as creatinine levels rose in the intermediate levels (Fig. 1) . This progression of hearing loss was not related to age. Overall, we observed an increased incidence of SNHL in patients with diabetes and that worse control of diabetes, as measured by increased creatinine, correlated with progressive loss of hearing independent of patient age.
A review of the literature and these data suggests a moderate link between poor blood sugar control and progression of hearing loss. Because audiologic data from patients with diabetes not experiencing hearing loss was not available, the exact impact of diabetes on hearing loss is still not clear. However, this study does demonstrate that data mining can be used to identify poorly defined disease relationships and suggests that screening all patients with diabetes for hearing loss in a prospective manner may be useful for a clearer understanding of this disease process.
